---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-008386"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:30:43.087466+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Vanda appoints Dr. Tage Honoré to Board, expanding from 5 to 6 directors

## Summary
- Board expanded to six members, five independent; Dr. Honoré appointed as Class I director.
- Initial equity grant $337,500 (50% options, 50% RSUs) + $50k annual retainer.
- Annual equity award $225,000 after each annual meeting; change-of-control acceleration.
- Dr. Honoré held exec roles at Novo Nordisk, Novartis, Purdue; discovered AMPA receptors.
- No related party transactions; independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001628280-23-008386
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828023008386/0001628280-23-008386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828023008386/vnda-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-008386
- JSON: https://secwatch.observer/filing/0001628280-23-008386.json
- Plain text: https://secwatch.observer/filing/0001628280-23-008386.txt

## Key facts
- Executive change
  Tage Honoré was appointed as director at Vanda Pharmaceuticals Inc..
  - Action: appointed
  - Role: director
  source text: On March 15, 2023, the Board of Directors (the “Board”) of Vanda Pharmaceuticals Inc. (the “Company”) expanded the size of the Board from five to six members, effective immediately and appointed Tage Honoré, Ph.D., D.Sc., as a director of the Company to fill the vacancy created by the expansion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828023008386/0001628280-23-008386-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.